Addex Therapeutics (ADXN) Share-based Compensation (2019 - 2026)

Addex Therapeutics has disclosed Share-based Compensation across 8 years of filings, most recently posting $29252.3 for Q1 2026.

• In Q1 2026, Share-based Compensation rose 5.55% year-over-year to $29252.3; the TTM figure through Mar 2026 stood at $85838.6 (down 46.35% YoY), while the FY2025 annual figure was $2.1 million, up 91.53% from the prior year.
• Share-based Compensation came in at $29252.3 for Q1 2026 at Addex Therapeutics, up from $14533.6 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.6 million in Q1 2022 to a low of $14533.6 in Q4 2025.
• Average Share-based Compensation over 5 years is $386500.1, with a median of $438773.1 recorded in 2023.
• Year-over-year, Share-based Compensation soared 657.53% in 2022 and plunged 93.73% in 2025.
• Over 5 years, Share-based Compensation stood at $710802.1 in 2022, then plunged by 38.27% to $438773.1 in 2023, then tumbled by 91.87% to $35684.0 in 2024, then slumped by 59.27% to $14533.6 in 2025, then soared by 101.27% to $29252.3 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $29252.3 in Q1 2026, $14533.6 in Q4 2025, and $18884.2 in Q3 2025.